Jump to content

Mirela Delibegovic

Edit links
From Wikipedia, the free encyclopedia
Mirela Delibegovic
FRSE
Born
Tuzla
Alma materUniversity of Dundee
University of Edinburgh
Scientific career
InstitutionsGlaxoSmithKline
Harvard Medical School
University of Aberdeen
ThesisIn vivo effects of insulin on the glycogen targeted forms of protein phosphatase 1 (2003)

Mirela Delibegovic, FRSE is a Bosnian-British pharmacologist/biochemist who is Dean for Industrial Engagement in Research & Knowledge Transfer and Director of Aberdeen Cardiovascular and Diabetes Centre. She is also Regius Professor of Physiology at the University of Aberdeen. During the COVID-19 pandemic, Delibegovic used artificial intelligence to develop technologies that would allow mass-screening for coronavirus disease 2019.

Early life and education

[edit]

Delibegovic is from Tuzla in Bosnia and Herzegovina.[1] She grew up during the Bosnian War, which forced her family apart. In the early nineties, she moved to Scotland and finished her secondary school education at George Heriot's School in Edinburgh.[2] Delibegovic studied pharmacology at the University of Edinburgh.[3] In the final year of her undergraduate degree Delibegovic moved to Essex, where she did her undergraduate final year project at GlaxoSmithKline on novel anti-diabetes drugs.[3] She completed her doctoral research with Prof Dame Patricia Cohen at the University of Dundee Medical Research Council Protein Phosphorylation Unit.[4] Here she studied the way that enzymes such as protein phosphatase 1 influenced diabetes development. She was supported by the Royal Society studentship. She has said that she was interested in diabetes because of family history and prevalence of Type 2 diabetes in Bosnia and Herzegovina.[3] During her doctoral research, Delibegovic worked closely with pharmaceutical companies to translate her research to the read world.[4] In 2003 she was awarded the American Heart Association personal fellowship to study the role of PTPN1 in glucose homeostasis at the Harvard Medical School in Boston, USA. She spent four years in Boston, working with Prof Benjamin Neel on mouse models of insulin resistance.[5]

Research and career

[edit]

In 2007 Delibegovic returned to the United Kingdom, where she was awarded the Research Councils UK 5-year tenure track fellowship to investigate obesity and ageing at the University of Aberdeen. She was made Professor in Diabetes Physiology in 2015 at the age of 38. The field of her research has focussed on the PTP1B phosphatase, the molecular mechanisms that cause diabetes and what the relationship is between diabetes and Alzheimer's disease.[2] She has demonstrated that PTP1B can be used for targeted treatments, reaching the cells of specific organs without causing any side effects.[4][6] In 2017 Delibegovic demonstrated a novel pharmaceutical, Trodusquemine, that could be used to treat type 2 diabetes and breast cancer. She went on to show that a single dose of Trodusquemine, the PTP1B inhibitor, could be used to reverse the effects of atherosclerosis.[7]

During the COVID-19 pandemic, Delibegovic, in collaboration with an SME Vertebrate Antibodies Ltd and the NHS Grampian, obtained funding from the Scottish Government/ Chief Scientist office to develop a diagnostic test that could support mass screening for coronavirus disease.[8] Her long-term aim was to use artificial intelligence[9][10] to identify which parts of the severe acute respiratory syndrome coronavirus 2 activated the body's immune system.[8][11] At the time, other coronavirus disease tests available in the United Kingdom would not support rapid deployment, and several were unreliable.[12][13] In May 2020, the tests developed by Delibegovic and her team were in development.[14] In March 2021, the tests were developed and available. https://www.abdn.ac.uk/news/14759/

In June 2024 she was appointed Regius Professor of Physiology at the University of Aberdeen.[15]

Awards and honours

[edit]

Selected publications

[edit]
  • Bence, Kendra K.; Delibegovic, Mirela; Xue, Bingzhong; Gorgun, Cem Z.; Hotamisligil, Gokhan S.; Neel, Benjamin G.; Kahn, Barbara B. (2006). "Neuronal PTP1B regulates body weight, adiposity and leptin action". Nature Medicine. 12 (8): 917–924. doi:10.1038/nm1435. ISSN 1546-170X. PMID 16845389. S2CID 10654045.[20]
  • Delibegovic, Mirela; Zimmer, Derek; Kauffman, Caitlin; Rak, Kimberly; Hong, Eun-Gyoung; Cho, You-Ree; Kim, Jason K.; Kahn, Barbara B.; Neel, Benjamin G.; Bence, Kendra K. (2009-03-01). "Liver-Specific Deletion of Protein-Tyrosine Phosphatase 1B (PTP1B) Improves Metabolic Syndrome and Attenuates Diet-Induced Endoplasmic Reticulum Stress". Diabetes. 58 (3): 590–599. doi:10.2337/db08-0913. ISSN 0012-1797. PMC 2646057. PMID 19074988.[5]
  • Delibegovic, Mirela; Bence, Kendra K.; Mody, Nimesh; Hong, Eun-Gyoung; Ko, Hwi Jin; Kim, Jason K.; Kahn, Barbara B.; Neel, Benjamin G. (2007-11-01). "Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B". Molecular and Cellular Biology. 27 (21): 7727–7734. doi:10.1128/MCB.00959-07. ISSN 0270-7306. PMC 2169063. PMID 17724080.[21]

Personal life

[edit]

Delibegovic met her husband whilst a graduate student at the University of Dundee.[4]

References

[edit]
  1. ^ "Doctor Mirjana Delibegovic from Tuzla invented a Medicine used in the Treatment of Diabetes and Breast Cancer". Sarajevo Times. 2017-11-07. Retrieved 2020-05-12.
  2. ^ a b "Professor Mirela Delibegovic | Staff Profile | The Institute of Medical Sciences | The University of Aberdeen". www.abdn.ac.uk. Retrieved 2020-05-12.
  3. ^ a b c "Science Scotland". www.sciencescotland.org. Retrieved 2020-05-12.
  4. ^ a b c d Lambert, Hazel. "Alumni Interview | Mirela Delibegovic". Retrieved 2020-05-12.
  5. ^ a b Delibegovic, Mirela; Zimmer, Derek; Kauffman, Caitlin; Rak, Kimberly; Hong, Eun-Gyoung; Cho, You-Ree; Kim, Jason K.; Kahn, Barbara B.; Neel, Benjamin G.; Bence, Kendra K. (2009-03-01). "Liver-Specific Deletion of Protein-Tyrosine Phosphatase 1B (PTP1B) Improves Metabolic Syndrome and Attenuates Diet-Induced Endoplasmic Reticulum Stress". Diabetes. 58 (3): 590–599. doi:10.2337/db08-0913. ISSN 0012-1797. PMC 2646057. PMID 19074988.
  6. ^ Grant, Louise; Shearer, Kirsty D.; Czopek, Alicja; Lees, Emma K.; Owen, Carl; Agouni, Abdelali; Workman, James; Martin-Granados, Cristina; Forrester, John V.; Wilson, Heather M.; Mody, Nimesh (2014-02-01). "Myeloid-Cell Protein Tyrosine Phosphatase-1B Deficiency in Mice Protects Against High-Fat Diet and Lipopolysaccharide-Induced Inflammation, Hyperinsulinemia, and Endotoxemia Through an IL-10 STAT3-Dependent Mechanism". Diabetes. 63 (2): 456–470. doi:10.2337/db13-0885. hdl:2164/4556. ISSN 0012-1797. PMID 24186864.
  7. ^ McCann, Lee (16 November 2016). "Aberdeen researchers find breast cancer drug can 'melt away' fat inside arteries". Evening Express. Retrieved 2020-05-14.
  8. ^ a b theorkneynews (2020-05-08). "Fast Tracking Tests for Covid19 Mass Screening". The Orkney News. Retrieved 2020-05-12.
  9. ^ Puttick, Helen. "Coronavirus in Scotland: Pledge to mass test for immunity by winter". The Times. ISSN 0140-0460. Retrieved 2020-05-12.
  10. ^ Easton, Kaitlin (6 May 2020). "Aberdeen University will use innovative approach to tackle Covid-19". Press and Journal. Retrieved 2020-05-14.
  11. ^ "University of Aberdeen Portfolio – Chief Scientist Office". www.cso.scot.nhs.uk. Retrieved 2020-05-12.
  12. ^ "Škotska: Tuzlanka Mirela Delibegović razvija test za masovni skrining na Covid-19". BHDINFODESK. 2020-05-09. Retrieved 2020-05-12.
  13. ^ McKee, Selina (2020-05-06). "Aberdeen Uni proceeds with COVID-19 mass screening research". PharmaTimes. Retrieved 2020-05-12.
  14. ^ Puttick, Helen. "Coronavirus in Scotland: Pledge to mass test for immunity by winter". The Times. ISSN 0140-0460. Retrieved 2020-05-12.
  15. ^ "No. 64452". The London Gazette. 8 July 2024. p. 13158.
  16. ^ "Royal Society of Edinburgh (RSE) Young Academy of Scotland". The University of Aberdeen. Retrieved 2020-05-12.
  17. ^ "Principal's Prize for Public Engagement with Research | Public Engagement with Research | The University of Aberdeen". www.abdn.ac.uk. Retrieved 2020-05-12.
  18. ^ "(FOTO) ŽENE DONIJELE JEDNOGLASNU ODLUKU: Razija Mujanović je dobitnica priznanja "Super žena 2017."". Kameleon M&M (in Bosnian). 2018-04-21. Retrieved 2020-05-12.
  19. ^ Thomas, James (2022-03-22). "Academic and artistic minds honoured as RSE Fellows". Royal Society of Edinburgh. Retrieved 2022-12-15.
  20. ^ Bence, Kendra K.; Delibegovic, Mirela; Xue, Bingzhong; Gorgun, Cem Z.; Hotamisligil, Gokhan S.; Neel, Benjamin G.; Kahn, Barbara B. (2006). "Neuronal PTP1B regulates body weight, adiposity and leptin action". Nature Medicine. 12 (8): 917–924. doi:10.1038/nm1435. ISSN 1546-170X. PMID 16845389. S2CID 10654045.
  21. ^ Delibegovic, Mirela; Bence, Kendra K.; Mody, Nimesh; Hong, Eun-Gyoung; Ko, Hwi Jin; Kim, Jason K.; Kahn, Barbara B.; Neel, Benjamin G. (2007-11-01). "Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B". Molecular and Cellular Biology. 27 (21): 7727–7734. doi:10.1128/MCB.00959-07. ISSN 0270-7306. PMC 2169063. PMID 17724080.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mirela_Delibegovic&oldid=1251665148"